Skip to main content
Pharmena S.A. logo

Pharmena S.A. — Investor Relations & Filings

Ticker · PHR ISIN · PLPHRMN00011 LEI · 259400RHT936BBKW0955 WAR Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2019-05-24 Management Reports
Country PL Poland
Listing WAR PHR

About Pharmena S.A.

https://www.pharmena.eu/

Pharmena S.A. is a specialty healthcare company focused on the development and commercialization of innovative products based on its patented active ingredient, 1-MNA. This molecule is a naturally occurring metabolite of niacin (vitamin B3) that plays a crucial role in cellular metabolism. The company's technology leverages the ability of 1-MNA to optimize the levels of the coenzyme NAD+, which decline with age and are vital for cellular function and regeneration. The product portfolio includes specialized cosmeceuticals, such as the Dermena line for hair loss, and dietary supplements designed to address the effects of cellular aging.

Recent filings

Filing Released Lang Actions
Wprowadzenie do sprzedaży w Polsce kolejnych suplementów diety z linii MENAVITIN - Content (PL)
Management Reports Classification · 99% confidence The document is a formal announcement by the Management Board ('Zarząd PHARMENA S.A.') referencing previous reports and detailing the launch of new dietary supplements (MENAVITIN VITAL and MENAVITIN ENDOTELIO) in Poland and outlining expansion plans for the EU market (Germany, Austria, Switzerland, etc.). This content relates to product strategy, sales execution, and market outlook, which falls under the scope of management reporting on business activities and outlook. Since it is not a full financial report (10-K or IR), an earnings release (ER), or a specific legal/governance filing, the most appropriate category is Management Reports (MDA), which covers management's explanation of business trends and outlook. Document length (3275 chars) is not indicative of a mere announcement of a report (RPA/RNS).
2019-05-24 Polish
Uchwała Zarządu o przydziale akcji serii E - Content (PL)
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document text, written in Polish, discusses the completion ('doszła do skutku') of the issuance (emisja) of 2,638,516 Series E ordinary bearer shares as part of a private subscription, referencing a resolution from an Extraordinary General Meeting (Nadzwyczajne Walne Zgromadzenie). It details the allocation of 2,189,706 shares and confirms they were fully paid for at an issue price of PLN 6.00 per share. This content directly relates to changes in the company's capital structure, specifically the issuance of new shares following a resolution, which aligns perfectly with the 'Capital/Financing Update' definition.
2019-05-23 Polish
PHARMENA Projekty uchwał na ZWZ w dniu 25 06 2019
AGM Information Classification · 99% confidence The document text is titled 'Projekty uchwał Zwyczajnego Walnego Zgromadzenia' which translates to 'Draft resolutions of the Ordinary General Meeting'. The content consists entirely of numbered resolutions ('Uchwała nr X') being voted upon or approved by the General Meeting concerning the approval of annual reports (for 2018), distribution of profit, and granting of 'absolutorium' (discharge/approval of performance) to board and supervisory council members for the 2018 fiscal year. This content is characteristic of the proceedings and resolutions passed at an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information).
2019-05-17 Polish
Projekty uchwał na Zwyczajne Walne Zgromadzenie na dzień 25 czerwca 2019 r. - Content (PL)
AGM Information Classification · 98% confidence The document text is very short (693 characters) and explicitly states that the Management Board is providing the content of draft resolutions ('treść projektów uchwał') that will be the subject of the Ordinary General Meeting ('Zwyczajnego Walnego Zgromadzenia') scheduled for June 25, 2019. This content relates directly to the agenda and proposals for the AGM. While it contains draft resolutions, the context is the announcement and preparation for the AGM itself. This strongly aligns with the purpose of an AGM-related filing, specifically the materials presented for the meeting, which falls under 'AGM Information' (AGM-R). It is not a general regulatory filing (RNS) because it is highly specific to the AGM agenda.
2019-05-17 Polish
PHARMENA 2019 Ogłoszenie o zwołaniu ZWZ w dniu 25 06 2019
AGM Information Classification · 100% confidence The document is titled "Ogłoszenie o zwołaniu Zwyczajnego Walnego Zgromadzenia Spółki..." which translates to "Announcement of the convening of the Ordinary General Meeting of the Company...". It details the date, time, location, and the full agenda (Porządek obrad) for a shareholder meeting scheduled for June 25, 2019. It also outlines procedures for shareholder registration, submitting proposals, and appointing proxies. This content directly corresponds to the definition of materials shared during an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information).
2019-05-17 Polish
Zwołanie Zwyczajnego Walnego Zgromadzenia spółki Pharmena S.A. - Content (PL)
AGM Information Classification · 98% confidence The document text is very short (803 characters) and explicitly states that the Management Board ('Zarząd') is announcing the convening ('zwołaniu') of an Annual General Meeting ('Zwyczajnego Walnego Zgromadzenia') scheduled for June 25, 2019. It also mentions that the announcement regarding the convening of the AGM is attached/being provided. This content directly relates to the scheduling and announcement of the AGM, which corresponds to the 'AGM Information' category.
2019-05-17 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.